Complex Biological Analysis
Made Simple
Genetic Microdevices
About Us
Technology
Investor Relations
Our Vision
We aspire to become global leaders in analytical and diagnostic devices and to sustain high growth through innovation.
Ultimately, we aim to democratise access to state-of-the-art biological analyses by dramatically reducing costs.
Meet The Team
At Genetic Microdevices, we have very high aspirations to capture a significant fraction of the Medtech and Diagnostic markets.
The company is led by Dimitrios Sideris who is founder and CEO. Our Board of Directors consists of experienced, highly skilled individuals who have excelled in their field and have shown strong & lasting commitment to the vision of the company.
The commercial and technical management team is currently being enriched with world-wide leaders who forge confidence in achieving our ambitious goals.
Dimitrios Sideris
CEO
Dimitrios is the inventor of the core technology and founder of GMD. He has over 15 years experience in developing and commercialising analytical instruments in the biotechnology and healthcare field. Dimitrios has a PhD in particle physics from Imperial College London. He is a technology entrepreneur with ambitious vision. 
Ken Freeman
CFO
Experienced venture capitalist, CFO (biotech and vc) and Board Member (biotech, software and non-profit) and cofounded a biotech company in Germany.
He has a MBA Harvard, MPA Harvard and Ph.D. KCL and has been a CFO of biotech companies in Ireland and the Netherlands.
Andreas Manz PhD
Scientific Advisor
A pioneer of microchip technology used for chemical applications. Development of high speed analyzers based on electrophoresis, chromatography and flow injection. Based on the micro-fabrication originally developed for microelectronics.
Developed a novel concept for Miniaturized Total Analysis Systems (µ-TAS). Published over 220 papers in scientific journals, which are cited over 16,000 times.
Tim Watts
UK ADVISORY BOARD
Former biotech CFO in both PLC (Oxford BioMedica, OXB) and private equity backed (Archimedes Pharma) companies and extensive experience in Big Pharma (AstraZeneca). General management experience gained through membership of senior executive teams at OXB (2012-2017) and Archimedes (2007-2011), and AZ International Sales & MarketingOrganisation (1999-2002). 
Harold Swerdlow
CTO
Harold Swerdlow played a pivotal role in the evolution of next-generation DNA sequencing technologies, both through his work at Solexa/Illumina and as the pioneer of using capillary electrophoresis for DNA sequencing.
At Solexa, he significantly advanced sequencing-by-synthesis technology, crucial for reducing the cost and time of DNA sequencing.
As the first scientist to demonstrate DNA sequencing utilizing capillary electrophoresis, he transformed DNA analysis by offering a scalable and precise alternative to traditional methods. Swerdlow's contributions have been foundational, enabling significant advancements in genomics and personalized medicine. 
Get In Touch
Unit 6, Princess Mews
Horace Road
Kingston upon Thames
Surrey, KT1 2SZ – UK
United Kingdom
GMD USA Inc
Call: +1 (646) 394-9098
United States of America
Get In touch
Leave us a message
GMD UK
Unit 6, Princess Mews,
Horace Road
Kingston upon Thames,
Surrey, KT1 2SZ
UK
GMD USA Inc
8 The Green
Suite B
City Of Dover
Kent County
Delaware 19901
United States of America